BSX · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 71 · Surprise 60 · No source text

Boston Scientific agreed to acquire 100% of Penumbra for approximately $14.5 billion, valued at $374 per share when announced on January 15, 2026. Penumbra stockholders approved the transaction on May 6, 2026, and the companies were responding to an FTC Second Request; closing was expected in early 2027 subject to regulatory clearances and other conditions. The company planned to fund approximately $11.0 billion of consideration with cash and newly issued debt, with the remainder paid in Boston Scientific shares, and to integrate Penumbra into its Cardiovascular division. Separately, a Blackstone Life Sciences agreement entered on October 2, 2026 provides for up to $455 million of development-cost funding for VITALYST, in exchange for potential milestone payments of up to 2.5 times Blackstone’s funded amount and royalties after U.S. approval.

Key facts

• Boston Scientific announced a definitive agreement on January 15, 2026 to acquire all of Penumbra for $374 per share, or approximately $14.500 billion. source
• Under an October 2, 2026 agreement, Blackstone Life Sciences would co-fund development of Boston Scientific's VITALYST Temporary Percutaneous Transvalvular Circulatory Support System; Boston Scientific may receive up to $455 million through U.S. regulatory approval, based on qualifying development costs. source
• Boston Scientific planned to fund the Penumbra acquisition with cash and approximately $11.000 billion of newly issued debt, with the remaining consideration paid in Boston Scientific common shares; Penumbra would be integrated into the Cardiovascular division. source
• Boston Scientific and Penumbra received an FTC Second Request on March 16, 2026; Penumbra stockholders approved the acquisition on May 6, 2026, and closing was expected in early 2027 subject to customary conditions including regulatory clearances. source
• After U.S. regulatory approval of VITALYST, Blackstone may receive fixed regulatory and commercial milestone payments of up to 2.5 times its actual funded amount and royalties on net sales. source
• Boston Scientific paid $930 million net for acquisitions of multiple businesses in the first nine months of 2026, primarily related to Nalu Medical and Scivita Medical Technology. source
• Boston Scientific made $1.545 billion of net payments for investments and acquisitions of technologies in the first nine months of 2026, primarily related to its investment in MiRus LLC. source

Impact estimates